M. Kiessling

发表

A PP4 holoenzyme balances physiological and oncogenic nuclear factor-kappa B signaling in T lymphocytes.

C. Klemke, M. Boutros, P. Krammer, 2012, Immunity.

Novel Role for Mitochondria: Protein Kinase Cθ-Dependent Oxidative Signaling Organelles in Activation-Induced T-Cell Death

P. Krammer, M. Kamiński, K. Gülow, 2007, Molecular and Cellular Biology.

Targeting ALK in Neuroendocrine Tumors of the Lung

J. Rüschoff, M. Rechsteiner, S. Höller, 2022, Frontiers in Oncology.

Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo‐mobilization with vinorelbine in multiple myeloma patients

R. Stupp, B. Seifert, M. Bargetzi, 2017, Journal of clinical apheresis.

Inhibition of NF‐κB induces a switch from CD95L‐dependent to CD95L‐independent and JNK‐mediated apoptosis in T cells

P. Krammer, K. Gülow, M. Brechmann, 2010, FEBS letters.

Author Correction: Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells

Ashton C. Berger, W. Hahn, M. Meyerson, 2018, Nature Communications.

Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.

Geraldine Rauch, Walter E Haefeli, David Czock, 2013, British journal of clinical pharmacology.

No life without death.

P. Krammer, M. Kamiński, K. Gülow, 2007, Advances in cancer research.

Correction: Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma

A. Aguzzi, J. Maris, G. Rogler, 2017, PloS one.

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma

A. Aguzzi, J. Maris, G. Rogler, 2016, PloS one.

Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E–Mutated Metastatic Colorectal Cancer

C. Britschgi, M. Rechsteiner, A. Weber, 2021, JCO Precision Oncology.

Author Correction: Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells

Ashton C. Berger, W. Hahn, M. Meyerson, 2018, Nature Communications.

Targeting the RAS pathway by mitogen-activated protein kinase inhibitors.

G. Rogler, M. Kiessling, 2015, Swiss medical weekly.

Mutant HRAS as novel target for MEK and mTOR inhibitors

Panagiotis Samaras, G. Rogler, K. Atrott, 2015, Oncotarget.

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.

C. Klemke, L. Garraway, L. French, 2011, Blood.

A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib.

H. Moch, R. Stahel, P. Wild, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

J. Tchinda, T. Bouwmeester, S. Schuierer, 2016, BMC Genomics.

Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma.

C. Klemke, P. Krammer, M. Kamiński, 2009, Cancer research.